Claudia Angela M. Fulgenzi
@FulgenziClaudia
Medical Oncologist; PhD student; Imperial College, London; University Campus Bio-Medico interested in HCC; KS and HIV-induced malignancies
ID:1385862696520798216
24-04-2021 07:46:41
92 Tweets
384 Followers
408 Following
Follow People
David James Pinato 🇺🇦
Medical Oncologist, MD PhD, Director of Developmental Therapeutics @ImperialCollege & @UniAvogadro ❤️ HCC, Immunotherapy and drug development. 🇮🇹 🇬🇧 🏳️🌈
Antonio D'Alessio
Medical Oncologist and PhD student at Imperial College London. HCC, immuno-oncology. Curiosity-driven.
Lorenza Rimassa
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma
Arndt Vogel
Clinician-scientist, focused on liver cancer & precision oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
Paolo Tarantino
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music.
Two new studies hint at a greater understanding of how to apply #immunotherapy in early and advanced #HCC , but also highlight complexities and gaps in this rapidly evolving field.
News & Views from David James Pinato 🇺🇦 & colleagues @ImperialCollege UPO - Università
nature.com/articles/s4159…
Immunotherapy is truly changing all stages of hepatocellular carcinoma. Honoured to have been tasked to make sense of this change with Antonio D'Alessio Claudia Angela M. Fulgenzi for Nature Medicine Surgery and Cancer UPO - Università nature.com/articles/s4159…
Honoured to share our News&Views published on Nature Medicine today 🗞️ our thoughts on adjuvant sintilimab and rego+nivo (RENOBATE trial) 🩺
ICIs in HCC are getting 'here, there, and everywhere'🌍 David James Pinato 🇺🇦 Claudia Angela M. Fulgenzi nature.com/articles/s4159…
As ‘23 draws to an end and out of office reply is solidly on I’d like to celebrate my promotion to Clinical Reader/Associate Professor👨🎓 Imperial College London UPO - Università
Busy HCC agenda in ‘24
Starting strong with a joint vision from 2 institutions willing to make a difference 👨🔬
.Andrea Napolitano giving us updates on the latest clinical trials in #leiomyosarcoma
Nice crossword puzzle!!😄
What a privilege to hear from Hanahan his views on the Hallmarks of cancer in 2023 🔬 more than two decades in the making - who would've guessed in 2000 that polymorphic microbiomes would become a hallmark of cancer?
ESMO - Eur. Oncology #ESMO23 Claudia Angela M. Fulgenzi
Grateful for the occasion to share ideas with friends and colleagues! See you at #ESMO23 Annual Conference in Madrid. Antonio D'Alessio Alessio Cortellini Andrea Napolitano @A_CammarotaMD David James Pinato 🇺🇦 Dr Ravindhi Murphy
Antonio D'Alessio brings home to the team an exceptional result following for the third year running Claudia Angela M. Fulgenzi and Petros Fessas in a long series of ILCA awards - beyond proud 🥲🔥
What a pleasure to present our preliminary data on the prognostic value of machine-learning derived #TILs -counts in #HCC today at #ILCA2023 - thank you for the opportunity and the great conference! David James Pinato 🇺🇦 Antonio D'Alessio Matthias Pinter Imperial College London MedUni Wien
🔥off the press: Immune Checkpoint Inhibitors for CP B HCC: Systematic Review & Meta-Analysis
JAMA Oncology
doi.org/10.1001/jamaon…
🔎we provide comprehensive summary: 22 studies/699 pts
👉Data support use of ICI in CP B, but we need prospective data
ESMO - Eur. Oncology ILCA EASL Education…
The price and value of therapeutic synergy in liver cancer ⚖️ - celebrating the lifetime honour of writing for The Lancet Surgery and Cancer UPO - Università Ciro Celsa Claudia Angela M. Fulgenzi Antonio D'Alessio Giulia Francesca Manfredi sciencedirect.com/science/articl…
Grateful to have been involved in this illuminating study dissecting the TME of HCC in PLHIV. Thanks to my Team David James Pinato 🇺🇦 Antonio D'Alessio for having amazingly brought the research forward.
More evidence are needed for a population too often excluded from RCT.
Surgery and Cancer
Very proud of Claudia Angela M. Fulgenzi 🥳 for challenging the dogma of systemic and in particular immunotherapy in CP-B liver dysfunction. ⚗️🩺 Much needed data to broaden the reach of systemic therapy in patients with #Hcc #WCGIC2023 ESMO - Eur. Oncology Surgery and Cancer Angela Lamarca
Grateful to present the results of our latest work at #WCGIC2023 . Thanks for the provocative discussion led by Angela Lamarca
More data are needed to recommend the best for our patients with CP-B liver dysfunction and HCC!
David James Pinato 🇺🇦 Antonio D'Alessio Surgery and Cancer ESMO - Eur. Oncology
Very happy to be here at #WCGIC2023 spending some time with my colleague Claudia Angela M. Fulgenzi! So proud to see you discuss with the great Angela Lamarca
#oncology #oncology research #hcc
Thank you Grainne O'Kane Shivan Sivakumar Claudia Angela M. Fulgenzi and Marcel den Dunk Maastricht University for fantastic talks about hot topics, challenges and opportunities in #HPB cancers Oncology Forum UK Prof David K. Chang #OF23
The authors of today’s #readoftheweek 📚 performed a network metanalysis of phase III of trials to compare first-line systemic treatments for #HCC .
Read here this🔓 #openaccess JHEP Reports article: bit.ly/3pU6aXW
🙏David James Pinato 🇺🇦 et al.
#LiverTwitter
To treat or not to treat? And most importantly, when to treat? 💊 Brilliant talk by David James Pinato 🇺🇦 about bringing forward IO to early-stage HCC #LiverCancerSummit2023 EASL Education EASLnews Claudia Angela M. Fulgenzi Bernhard Scheiner Surgery and Cancer
